None
EN
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
['Jason Mast', 'Brian Yang', 'Jason Is A General Assignment Reporter', 'With Particular Focus On Genetic Medicine', 'Rare Disease. Confidential Tips Can Be Sent On Signal At', 'General Assignment Reporter', 'A Freelance Reporter', 'Has Covered The Chinese Biopharma Industry For More Than Years. He Was Previously Managing Editor For Citeline S Scrip', 'Pink Sheet In Beijing.', 'Adam Feuerstein']
STAT
Last year, a little-known Chinese startup took center stage at the American Society for Gene and Cell Therapy annual convention in New Orleans.
But Luk said the data indicated benefit and the company was about to test a higher dose.
Luk quietly departed last summer, alongside Chief Technology Officer TJ Cradick, a longtime U.S.-based gene editing executive who had been there less than a year.
In February, a listing on a clinical trial registry was updated to announce the study was “complete.”
But after a monthslong STAT investigation and repeated questions to the company, HuidaGene on Wednesday issued an update.